Get In Touch

Global Resistant Hypertension Treatment Market: Overview

Hypertension is one of the common untreated diseases and poses major risk for heart failure, renal failure, cerebrovascular disease, cardiovascular disease, and coronary heart disease. About less than half of hypertensive patients in the U.S. are using economical generic antihypertensive drugs (AHDs). About 5%-10% (maximum to 20%-30%) of hypertensive patients with incompetently controlled hypertension have resistant hypertension. Resistant hypertension is a condition when the blood pressure remains higher than the normal range despite optimum dosage of three antihypertensive drugs, including a diuretics. Resistant hypertension includes patients whose blood pressure controlled on ≥ 4 antihypertensive drugs, but excludes those with uncontrolled blood pressure on <3 antihypertensive drugs or suboptimal antihypertensive drugs regimen. According to the latest research studies, prevalence rate of resistant hypertension is estimated to increase in the future. Resistant hypertension is found in patients with chronic kidney disease (CKD), left ventricular hypertrophy (LVH), diabetes, higher systolic BP, obesity, and also among elderly patients. Resistant hypertensive patients are at higher risk of serious cardiovascular outcomes, hospitalization, and heart stroke, in particular.

Global Resistant Hypertension Treatment Market: Drivers and Restraints

Resistant hypertension is different from uncontrolled hypertension. For a precise identification of prevalence of resistant hypertension, a compulsory titration study of a large and diverse hypertensive group is required. Resistant hypertension denotes a risky phenotype. Genetic factors play a more crucial role in resistant hypertension as compared to general hypertension. Although for resistant hypertensive patients, genetic valuations are limited. In one of the limited genetic assessments of patients in Finland, investigators screened 347 patients with resistant hypertension who had mutation on the γ and β subunits of the epithelial sodium channel.

Mutation on the γ and β subunits can cause Liddle’s syndrome. Liddle’s syndrome is a rare form of hypertension (monogenic). According to data collected by the National Health and Nutrition Examination Survey (NHANES) from its study of samples of non-institutionalized, adult, civilian population, the prevalence rate of resistant hypertension was estimated around 8.9?±?0.6% among the population of the U.S. during 2003 to 2008. The study suggests that resistant hypertension and hypertension have become wide-spread due to increase of obesity among the general population and growth in geriatric population. Resistant hypertension is more prevalent among the non-black Hispanic or African America, male, obese, and elderly population. The global resistant hypertension treatment market has been expanding over the years. Growth in geriatric population is a major factor boosting the resistant hypertension treatment market. Increase in consumption of alcohols, junk foods, etc. is another key driver of the resistant hypertension treatment market. However, ignorance and drug resistance are the main restraints of the resistant hypertension treatment market.

Global Resistant Hypertension Treatment Market: Key Segments

The global resistant hypertension treatment market can be segmented based on type of treatment, end-user, and region. In terms of type of treatment, the global resistant hypertension treatment market can be classified into diuretic therapy, combination therapy, mineralocorticoid receptor antagonists, and others. Based on end-user, the global resistant hypertension treatment market can be categorized into hospital pharmacy, retail pharmacy, and online pharmacy. In terms of region, the global resistant hypertension treatment market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global resistant hypertension treatment market due to availability of advanced medications in the region. Awareness regarding the disease is another factor boosting the resistant hypertension treatment market in North America. The resistant hypertension treatment market in Asia Pacific is anticipated to expand at a high growth rate due to increase in prevalence of the disease in the region. In Middle East & Africa, owing to unawareness about the disease in the underdeveloped countries such as Turkey, Cyprus, Syria, Lebanon, Iraq, etc. the resistant hypertension treatment market is expanding in the region.

Global Resistant Hypertension Treatment Market: Key Players

Key players operating in the global resistant hypertension treatment market are Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd., and Amgen Inc., among others.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Resistant Hypertension Treatment Market

Pre Book